OP0040 Bucillamine and its metabolites induce synthesis of vegf dose dependently in systemic sclerosis fibroblasts via the nf-kb pathway. (1st June 2001)

• Record Type: Journal Article
• Authors: Hagen, C; Distler, O; Müller-Ladner, U; Carossino, A; Gay, RE; Nanagara, R; Michel, BA; Nishioka, K; Matucci-Cerinic, M; Gay, S
• Is Part Of: Annals of the rheumatic diseases. Volume 60(2001)Supplement 1
• Page Start: A119
• Page End: A119
• Publication Date: 2001-06-01
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2001.297
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Bucillamine (BUC) is an immunomodulatory drug used in the treatment of rheumatoid arthritis with inhibitory effects on B- and T-cell functions. However, the impact of Bucillamine on metabolic pathways of fibroblasts has not been addressed. Objectives: Since an altered metabolism of fibroblasts is a hallmark of systemic sclerosis (SSc), we investigated whether BUC and its metabolites SA981 and SA679 influence the cytokine pattern of skin fibroblasts and might be of therapeutical use in SSc. Methods: Cultures of skin fibroblasts from 6 patients with SSc and 5 healthy controls were incubated with BUC, SA981 and SA679 at different concentrations for 6 to 24 h. Quantification for VEGF, IL-6 and TGF-b1 mRNA was performed with real-time PCR (TaqMan). Supernatants were analysed for VEGF by ELISA. In addition, fibroblasts were preincubated with the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC) and analysed for the expression of VEGF as describe above. The trypan blue dye exclusion test was used to assess the viability of the cells. The effects on the chemotactic activity of fibroblasts were examined in a modified Boyden chamber assay. Results: VEGF mRNA was increased in all fibroblast cultures after BUC treatment compared to non-treated controls, whereas no effect was observed on the levels of IL-6 and TGF-b1. VEGF mRNA increased dose dependently with both BUC and its metabolites. The most significant induction was observed after treatment with SA981 (1 mg/ml: 7.7 ± 4.3, 0, 6 mg/ml: 5.2 ± 2.3; 0, 15 mg/ml: 2.9 ± 1.4, 0, 05 mg/ml: 2.5 ± 1.9 fold increase, p < 0.05). Fibroblast cultures from patients with SSc showed a consistent higher inducibility of VEGF than cultures from healthy controls (SSc: 9.9 ± 4.3; healthy controls: 5.2 ± 2.8 fold increase, p < 0.05). These results were confirmed on the protein level with a significant rise of VEGF in SSc cultures, but not in healthy controls. The increase of VEGF was not due to unspecific toxicity, since the cell viability was >95% in treated and non-treated fibroblasts. Preincubation with the NF-kB inhibitor PDTC reduced the production of VEGF by 60%. Interestingly, there was a significant increase in the chemotactic activity of supernatants from fibroblasts treated with BUC (133 ± 39 cells/high power field = hpf), SA679 (72 ± 19 cells/hpf) and SA981 (43 ± 5 cells/hpf) compared to non-treated controls (26 ± 7 cells/hpf). Conclusion: Our results indicate that BUC and its metabolites, in addition to the known immunomodulatory effects, may have favourable influence on neoangiogenesis in SSc through the release of VEGF by skin fibroblasts. Since impaired angiogenesis and inflammatory infiltrates are hallmarks in the pathogenesis of SSc, BUC may be of benefit in the treatment of this disease.